Adaptive Biotechnologies Corporation (ADPT)
NASDAQ: ADPT · Real-Time Price · USD
13.00
+0.34 (2.69%)
At close: Aug 13, 2025, 4:00 PM
13.18
+0.18 (1.38%)
After-hours: Aug 13, 2025, 7:00 PM EDT
Adaptive Biotechnologies Revenue
Adaptive Biotechnologies had revenue of $58.88M in the quarter ending June 30, 2025, with 36.33% growth. This brings the company's revenue in the last twelve months to $205.22M, up 21.60% year-over-year. In the year 2024, Adaptive Biotechnologies had annual revenue of $178.96M with 5.10% growth.
Revenue (ttm)
$205.22M
Revenue Growth
+21.60%
P/S Ratio
9.20
Revenue / Employee
$331,528
Employees
619
Market Cap
1.98B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ADPT News
- 5 days ago - Aristotle Focus Growth Q2 Highlights: Top Performers, Surprises And Strategic Shifts - Seeking Alpha
- 7 days ago - Adaptive Biotechnologies Corporation (ADPT) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 8 days ago - Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025 - GlobeNewsWire
- 6 weeks ago - Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR® - GlobeNewsWire
- 2 months ago - Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers - GlobeNewsWire
- 2 months ago - Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewsWire
- 3 months ago - Adaptive Biotechnologies Corporation (ADPT) Q1 2025 Earnings Call Transcript - Seeking Alpha